Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,025 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms.
Narayan R, Benjamin JE, Shah O, Tian L, Tate K, Armstrong R, Xie BJ, Lowsky R, Laport G, Negrin RS, Meyer EH. Narayan R, et al. Biol Blood Marrow Transplant. 2019 Jul;25(7):1293-1303. doi: 10.1016/j.bbmt.2019.03.027. Epub 2019 Apr 3. Biol Blood Marrow Transplant. 2019. PMID: 30951840 Free PMC article. Clinical Trial.
HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid Leukemia.
Narayan R, Niroula A, Wang T, Kuxhausen M, He M, Meyer E, Chen YB, Bhatt VR, Beitinjaneh A, Nishihori T, Sharma A, Brown VI, Kamoun M, Diaz MA, Abid MB, Askar M, Kanakry CG, Gragert L, Bolon YT, Marsh SGE, Gadalla SM, Paczesny S, Spellman S, Lee SJ. Narayan R, et al. Transplant Cell Ther. 2023 Jul;29(7):452.e1-452.e11. doi: 10.1016/j.jtct.2023.03.027. Epub 2023 Mar 29. Transplant Cell Ther. 2023. PMID: 36997024 Free PMC article.
Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.
Kasbekar M, Nardi V, Dal Cin P, Brunner AM, Burke M, Chen YB, Connolly C, Fathi AT, Foster J, Macrae M, McAfee SL, McGregor K, Narayan R, Ramos AY, Som TT, Vartanian M, Friedman RS, Benhadji KA, Hobbs GS. Kasbekar M, et al. Among authors: narayan r. Blood Adv. 2020 Jul 14;4(13):3136-3140. doi: 10.1182/bloodadvances.2020002308. Blood Adv. 2020. PMID: 32649766 Free PMC article.
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.
Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, Mims AS, DeFilipp Z, El-Jawahri A, McAfee SL, Brunner AM, Narayan R, Knight LW, Kelley D, Bottoms AS, Perry LH, Wahl JL, Brock J, Breton E, Ho VT, Chen YB. Fathi AT, et al. Among authors: narayan r. Blood Adv. 2022 Nov 22;6(22):5857-5865. doi: 10.1182/bloodadvances.2022008632. Blood Adv. 2022. PMID: 36150050 Free PMC article. Clinical Trial.
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan R, Garcia JS, Percival ME, Berube C, Coutre S, Gotlib J, Greenberg P, Liedtke M, Hewitt R, Regan K, Williamson C, Doykan C, Cardone MH, McMillan A, Medeiros BC. Narayan R, et al. Leuk Lymphoma. 2016;57(3):609-15. doi: 10.3109/10428194.2015.1091930. Epub 2015 Oct 13. Leuk Lymphoma. 2016. PMID: 26374199 Clinical Trial.
1,025 results